While enzalutamide inhibited the proliferation of prostate cancer cell lines with a 5-fold difference in IC50 values between AR-positive and -negative prostate cancer cell lines, it inhibited TNBC cell lines at comparable concentrations regardless of the AR expression. Here, AR is linked to prostate carcinoma.